Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cumberland Pharmaceuticals (CPIX) Common Equity: 2009-2024

Historic Common Equity for Cumberland Pharmaceuticals (CPIX) over the last 16 years, with Dec 2024 value amounting to $22.9 million.

  • Cumberland Pharmaceuticals' Common Equity rose 5.41% to $26.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $26.1 million, marking a year-over-year increase of 5.41%. This contributed to the annual value of $22.9 million for FY2024, which is 22.80% down from last year.
  • Cumberland Pharmaceuticals' Common Equity amounted to $22.9 million in FY2024, which was down 22.80% from $29.6 million recorded in FY2023.
  • Cumberland Pharmaceuticals' 5-year Common Equity high stood at $47.0 million for FY2020, and its period low was $22.9 million during FY2024.
  • Moreover, its 3-year median value for Common Equity was $29.6 million (2023), whereas its average is $29.6 million.
  • Data for Cumberland Pharmaceuticals' Common Equity shows a maximum YoY decreased of 22.80% (in 2024) over the last 5 years.
  • Over the past 5 years, Cumberland Pharmaceuticals' Common Equity (Yearly) stood at $47.0 million in 2020, then decreased by 8.89% to $42.8 million in 2021, then dropped by 15.29% to $36.3 million in 2022, then fell by 18.37% to $29.6 million in 2023, then fell by 22.80% to $22.9 million in 2024.